Back to Feed
ClinicalTrials.gov|Clinical Trial
Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
David Wald
Abstract
This study seeks to determine the safety and efficacy of the infusion of autologous CD19 CAR-T cells that are manufactured using an ultra-fast process. Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: Non Hodgkin Lymphoma Interventions: UF-KURE19 CAR-T cells; Fludarabine; Cyclophosphamide
Keywords
Non Hodgkin Lymphoma